Business context and reporting period
The supplied filing is Bio Blast Pharma Ltd.’s audited Form 20-F for the fiscal year ended December 31, 2015, filed March 29, 2016. It is an annual report, not a standalone fourth-quarter filing. The request identifies Enlivex Ltd., but the filing identifies the registrant as Bio Blast Pharma Ltd. (Nasdaq: ORPN); the filing does not establish that these are the same company.
Bio Blast was a development-stage biopharmaceutical company developing treatments for rare and ultra-rare genetic diseases. Its lead candidate, intravenous trehalose, was in Phase 2 development; its mitochondrial protein replacement and read-through candidates were preclinical. Financial statements are in U.S. dollars and prepared under U.S. GAAP.
Financial results and liquidity
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.694 million | $4.441 million |
| Pre-commercialization expense | $0.829 million | None |
| General and administrative expense | $6.953 million | $2.639 million |
| Operating loss | $15.476 million | $7.080 million |
| Net loss | $15.365 million | $7.022 million |
| Net loss per ordinary share | $1.08 | $0.57 |
| Net cash used in operating activities | $13.249 million | $4.409 million |
| Cash and cash equivalents | $7.286 million | $10.583 million |
| Short-term bank deposits | $12.046 million | $22.028 million |
| Working capital | $17.878 million | $30.605 million |
| Total assets | $20.516 million | $32.954 million |
| Shareholders’ equity | $17.932 million | $30.674 million |
| Accumulated deficit | $23.787 million | $8.422 million |
Cash, cash equivalents, and short-term deposits totaled $19.332 million at year-end. Current liabilities were $2.514 million; the balance sheet also reports $70,000 of long-term liabilities. The filing reports no debt financing or off-balance-sheet arrangements. Gross margin is not applicable because the company had no product revenue.
Operating cash use rose to $13.249 million from $4.409 million. Investing activities provided $9.952 million, mainly from short-term deposits maturing; financing activities were zero in 2015. Cash and cash equivalents declined by $3.297 million during the year. Management said year-end liquidity would fund its current plan until at least the end of Q2 2017, but additional funding was needed to fully fund the planned Phase 2b study and ongoing operations.
Material changes versus the prior comparable period
- Net loss more than doubled, from $7.022 million to $15.365 million, as operating loss increased 118%.
- R&D expense rose 73%, primarily with increased clinical-trial, manufacturing, professional-service, and personnel costs. G&A expense rose to $6.953 million from $2.639 million, reflecting executive hiring, share-based compensation, and professional services.
- Pre-commercialization spending began in 2015, totaling $0.829 million, as the company expanded commercial assessment for trehalose.
- Working capital fell by $12.727 million, and cash plus short-term deposits declined from $32.611 million to $19.332 million.
- Share-based compensation was $2.623 million in 2015, versus $0.736 million in 2014; the filing reports 14,230,480 ordinary shares outstanding at year-end.
Outlook, commentary, risks, and unusual items
- Management planned to start a Phase 2b, double-blind, placebo-controlled OPMD trial during 2016, contingent on funding. It stated that available funds did not fully cover that study and operating costs while it was underway; absent funding, activities might be reduced.
- In March 2016, after year-end, the company issued 2,161,290 shares at $3.10 per share and warrants for up to 1,080,645 shares at $4.50. Gross proceeds were $6.7 million and net proceeds approximately $6.1 million.
- Also in March 2016, the company reported final results from the open-label HOPEMD Phase 2 OPMD trial. It reported no drug-related serious adverse events and improvements from baseline on several secondary swallowing and muscle-function measures. The trial was not powered to establish efficacy and had no placebo control; results do not establish effectiveness or predict later-trial outcomes. One participant died from aspiration pneumonia, which the company said was not drug-related.
- The company reported it had never generated product revenue and did not expect product revenue for the next few years. It remained dependent on external financing and warned that insufficient funding could delay, reduce, or terminate development programs and could raise substantial doubt about its ability to continue as a going concern.
- Key risks include clinical and regulatory failure, limited rare-disease patient pools and enrollment challenges, single-source suppliers and reliance on contract manufacturers, uncertain reimbursement and pricing, competition, patent and licensing risks, and foreign-exchange exposure. About 27% of 2015 expenses were denominated in NIS; the company did not hedge currency risk.
- The audited financial statements received an unqualified opinion from EY member firm Kost Forer Gabbay & Kasierer. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2015; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for Bio Blast Pharma Ltd., not Enlivex Ltd.
- Review the March 2016 financing’s net proceeds, warrant terms, and resulting dilution, and compare them with current cash needs.
- Verify the actual cash runway and funding required for the planned OPMD Phase 2b trial; the stated Q2 2017 runway was based on management’s then-current plan.
- Assess the full HOPEMD dataset, its open-label design and secondary endpoints, and subsequent controlled-trial plans and results.
- Check subsequent developments in clinical programs, regulatory status, supply arrangements, licensing obligations, and any material changes after the 2015 year-end.